Mitigation of gastrointestinal graft- versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination

Affiliations

• ¹ From the Bone Marrow Transplant and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin. schhabra@mcw.edu.
• ² Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin.
• ³ Department of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center.
• ⁴ Cancer Center Clinical Trials Office, Medical College of Wisconsin.
• ⁵ Department of Pharmacy, Froedtert Health.
• ⁶ Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center.
• ⁷ From the Bone Marrow Transplant and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin.
• ⁸ Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.
• ⁹ From the Bone Marrow Transplant and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin. wdrobysk@mcw.edu.